CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 12, 2013
Result type: Reports
Project Number: SR0351-000
Product Line: Reimbursement Review

Generic Name: Golimumab

Brand Name: Simponi I.V.

Manufacturer: Janssen Inc.

Therapeutic Area: Arthritis, rheumatoid

Indications: Arthritis, Rheumatoid

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 17, 2014

Recommendation Type: List with criteria/condition